OBI Pharma Email Formats

Biotechnology Research • 6F., No. 508, Taiwan, Province of China • 101-200 Employees

OBI Pharma Email Formats

OBI Pharma uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@obipharma.com), used 31.6% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@obipharma.com	58%
{first name}{last name}	johndoe@obipharma.com	36.9%

Key Contacts at OBI Pharma

Christa Maurer

Sr. Director, Quality Assurance

David Teng-Yi Huang

Senior Director

Qian Yang

Director, Regulatory Affairs Cmc Biologics

Wei Lee

Senior Director Cmc

Biotech Lee

Director

Neo Chien

Internal Audit Associate Director

南絢王

Associate Director Of Analytics Division

Pedro Chen

Director Of Business Analytic At Obi Pharma

Bob Chang

Associate Director

Emily Lin

Associate Director Of Regulatory Affairs

Company overview

Headquarters	6F., No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist.,, Nangang District, Taipei City, TAIWAN 11561, TW
Phone number	+886226558799
Website	obipharma.com
NAICS	541714
SIC	283
Keywords	Biotechnology, Oncology, Active Immunotherapy, Antibody-Drug Conjugate, Bispecific Adc, Dual Payload Adc
Employees	101-200
Socials

About OBI Pharma

OBI Pharma Inc. (OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by Dr. Michael Chang, an accomplished biotech entrepreneur in the United States. Its stocks were issued publicly in 2012. Subsequently, the company was successfully listed on the Taipei Exchange (4174.TWO) in 2015. OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs worldwide with a “Made in Taiwan” branding and to provide new treatment options for patients with unmet medical needs. The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADC) drugs for patients, in addition to its promising Globo series (e.g., Globo H) of cancer therapeutic vaccines. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin4, HER2, etc. These ADCs are built based on two distinct ADC technology platforms, each with different characteristics. Both platforms are customizable and offer a “plug-and-play” advantage through a specialized site-specific conjugation using a proprietary enzyme. With the added value of scalability, these “plug-and-play” technology platforms enable ADC development to be relatively simple and efficient. OBI is interested in commercializing its ADC technology platforms and looks forward to collaborating with biotech and pharmaceutical companies by enabling “first-in-class” and “best-in-class” therapeutic candidates for further development.